Brief: Spectrum Pharmaceuticals Announces Commercial Availability Of ROLVEDON™ (Eflapegrastim-Xnst) Injection
21/10/2022 12:51
Oct 21 (Reuters) - Spectrum Pharmaceuticals Inc
SPPI.O :
* SPECTRUM PHARMACEUTICALS ANNOUNCES COMMERCIAL AVAILABILITY
OF
ROLVEDON™ (EFLAPEGRASTIM-XNST) INJECTION
Source text for Eikon: ID:nBw5Tjhk0a
Further company coverage: SPPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary